Parker, Waichman, Alonso LLP

YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Anaphylactic Shock


AddThis Social Bookmark Button

Anaphylactic Shock

Anaphylactic shock, also known as anaphylaxis arises when a person ingests or comes into contact with a substance to which they are severely allergic. Prescription medicines, food, insect stings and latex commonly cause anaphylactic shock. This reaction can be life threatening and individuals with asthma, eczema, or hay fever are at greater relative risk of experiencing anaphylaxis. This allergic reaction may affect the skin, respiratory tract, gastrointestinal tract, and cardiovascular system.

Anaphylaxis symptoms happen within minutes to two hours after contact with the allergy-causing substance. In rare cases symptoms can take place up to 4 hours later. According to statistics, 30 out of 100,000 persons experience anaphylactic reactions yearly. An up to date study illustrated that teens with food allergy and asthma appear to be at highest risk for a reaction because they are more likely to eat away from home. Therefore they are less likely to bring medications, and they may disregard or not recognize symptoms.

Symptoms of Anaphylactic shock
  • Tingling sensation
  • Itching
  • Metallic taste in the mouth
  • Hives
  • Warm sensation
  • Asthma
  • Swelling of mouth & throat
  • Difficulty breathing
  • Vomiting
  • Diarrhea
  • Cramping
  • Drop in blood pressure
  • Loss of consciousness
If you or a loved one took a prescription medication and you went into Anaphylactic shock, please fill out the form at the right for a free case evaluation from one of our experienced defective drug attorneys.
Anaphylactic ShockRSS Feed

FDA Requests Label Change for All Sleep Disorder Drug Products

Mar 14, 2007 | www.fda.gov
The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory...

Xolair Linked to Risk for Delayed-Onset Anaphylaxis

Feb 22, 2007 | www.medscape.com
Omalizumab subcutaneous injection (Xolair, made by Genentech, Inc) may be linked to life-threatening anaphylaxis, according to a warning from the US Food and Drug Administration (FDA). Although most cases (71%) have occurred within 2 hours of omalizumab injection, some (13%) delayed-onset cases have been reported after 2 to more than 24 hours, according to an alert sent yesterday from MedWatch, the FDA's safety information and adverse event reporting program. The FDA notes that anaphylaxis can...

FDA Issues New Warning About Asthma Drug Xolair

Feb 22, 2007 | NewsInferno.com
Citing reports of severe, potentially fatal allergic reactions, the U.S. Food and Drug Administration (FDA) has issued a new warning about omalizumab, an asthma drug marketed by Genentech as Xolair. The agency has requested a “black box” warning be added to the product’s label reflecting the risk of anaphylaxis. Xolair was approved by the FDA in 2003 to treat patients with allergy-related asthma. It was previously believed that the risk of anaphylaxis was most severe within...

FDA orders stronger asthma drug warning

Feb 21, 2007 | AP
The government ordered stronger label warnings for an injected asthma medication Wednesday because of reports some patients taking the drug, marketed as Xolair, had suffered a delayed and potentially life-threatening reaction known as anaphylaxis. A patient experiencing anaphylaxis might have trouble breathing, feel tight in the chest, have swelling in the mouth and throat, suffer dizziness or feel faint, or have itching and hives. The risk of anaphylaxis was known when Xolair, also called...

FDA Proposes to Strengthen Label Warning for Xolair

Feb 21, 2007 | www.fda.gov
The Food and Drug Administration (FDA) announced that it has requested Genentech, Inc. add a boxed warning to the product label for omalizumab, marketed as Xolair. The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. Anaphylaxis may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat. In addition, FDA has asked Genentech to revise the Xolair label and provide...

More Anaphylactic Shock News

Diseases
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Please describe your disease, injury or medical condition:

What was the date of diagnosis?

What do you believe caused this disease (drug, toxic substance, etc.)?

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News